ceftobiprole medocaril
Phase 2Withdrawn 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedAbout ceftobiprole medocaril
ceftobiprole medocaril is a phase 2 stage product being developed by Basilea Pharmaceutica for Bacteremia. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT00505258. Target conditions include Bacteremia.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00505258 | Phase 2 | Withdrawn |
| NCT05856227 | Phase 3 | Completed |
| NCT02527681 | Phase 1 | Terminated |
Competing Products
9 competing products in Bacteremia
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Daptomycin + Comparator | Merck | Approved | 85 |
| Daptomycin for Injection | Merck | Phase 2 | 52 |
| Vancomycin + Daptomycin | Merck | Approved | 85 |
| Ceftolozane-Tazobactam + Meropenem | Merck | Phase 3 | 77 |
| Cefazolin IV + Linezolid IV + Vancomycin (IV) | Pfizer | Phase 3 | 76 |
| Aurexis® | Bristol Myers Squibb | Phase 2 | 51 |
| Ceftobiprole medocaril + Daptomycin | Basilea Pharmaceutica | Phase 3 | 72 |
| AP-SA02 | Armata Pharmaceuticals | Phase 1/2 | 33 |
| 514G3 (2 mg/kg) plus standard IV antibiotic treatment + 514G3 (10 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment + 514G3 (40 mg/kg) plus standard IV antibiotic treatment: Phase II | XBiotech | Phase 1/2 | 33 |